
Appeal could throw spanner in the works for Regeneron’s Irish expansion
pharmafile | March 9, 2018 | News story | Manufacturing and Production, Medical Communications | Ireland, Regeneron, pharma
Regeneron is facing a single man-sized obstacle in plans to expand operations at its campus in Limerick, Ireland with a new €20 million bulk biologics facility which could see delays of up to half a year.
One Michael Fenton has applied to independent Irish judicial body An Bord Pleanála to appeal the green light given by Limerick County Council. He did not object to the plans earlier in the process when the project was put before the council.
The US firm originally announced the plans in October last year. It has stated that the expansion will create 150 new permanent roles, made up of those from the local area as well as people relocating back to Ireland. Additionally, the company said that 137 roles would be created in the service industry, while the three-year construction project to build the new site would employ another 500 people.
The board is due to make a decision on the matter by the end of March, and it could mean the project could be delayed by four to six months if the ruling comes down on the side of Mr Fenton.
Matt Fellows
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Dupixent improves symptoms in patients with skin of colour, study shows
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at …






